Profund Advisors LLC Insmed Inc Transaction History

Profund Advisors LLC

$2.7 Billion
Q2 2025

A detailed history of Profund Advisors LLC transactions in Insmed Inc stock. As of the latest transaction made, Profund Advisors LLC holds 19,558 shares of INSM stock, worth $3.19 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

19,558

Previous 32,097 39.07%

Holding current value

$3.19 Million

Previous $2.45 Million 19.61%

% of portfolio

0.07%

Previous 0.11%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	SELL	$64.81 - $105.9 $812,652 - $1.33 Million	-12,539 Reduced 39.07%	19,558 $1.97 Million
Q1 2025 May 08, 2025	SELL	$65.25 - $83.83 $325,467 - $418,144	-4,988 Reduced 13.45%	32,097 $2.45 Million
Q4 2024 Feb 13, 2025	SELL	$66.29 - $76.63 $603,305 - $697,409	-9,101 Reduced 19.71%	37,085 $2.56 Million
Q3 2024 Nov 13, 2024	BUY	$62.0 - $79.01 $1.44 Million - $1.83 Million	23,166 Added 100.63%	46,186 $3.37 Million
Q2 2024 Aug 13, 2024	SELL	$22.0 - $69.71 $658,306 - $2.09 Million	-29,923 Reduced 56.52%	23,020 $1.54 Million
Q1 2024 May 08, 2024	SELL	$25.72 - $29.94 $27,880 - $32,454	-1,084 Reduced 2.01%	52,943 $1.44 Million
Q4 2023 Feb 14, 2024	BUY	$23.42 - $31.74 $148,482 - $201,231	6,340 Added 13.3%	54,027 $1.67 Million
Q3 2023 Nov 13, 2023	SELL	$19.86 - $26.93 $413,644 - $560,898	-20,828 Reduced 30.4%	47,687 $1.2 Million
Q2 2023 Aug 10, 2023	SELL	$16.44 - $21.1 $47,347 - $60,768	-2,880 Reduced 4.03%	68,515 $1.45 Million
Q1 2023 May 11, 2023	BUY	$16.26 - $21.73 $1.16 Million - $1.55 Million	71,395 New	71,395 $1.22 Million

Others Institutions Holding INSM

# of Institutions

582

Shares Held

203M

Call Options Held

2.84M

Put Options Held

3.26M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $22.1B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Account

Profund Advisors LLC Insmed Inc Transaction History